Fenofibrate - Veloxis Pharmaceuticals

Drug Profile

Fenofibrate - Veloxis Pharmaceuticals

Alternative Names: Fenoglide; LCP-FenoChol

Latest Information Update: 07 Apr 2015

Price : $50

At a glance

  • Originator LifeCycle Pharma
  • Developer Veloxis Pharmaceuticals
  • Class Antihyperlipidaemics; Benzophenones; Butyric acids; Fibric acid derivatives; Propionates; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hyperlipidaemia

Most Recent Events

  • 01 Apr 2015 Salix Pharmaceuticals has been acquired by Valeant Pharmaceuticals International
  • 02 Jan 2014 Santarus has been acquired and merged into Salix Pharmaceuticals
  • 22 Dec 2011 Fenofibrate licence in USA transferred from Shore Therapeutics to Santarus ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top